Current partner codePEPTIDESDE
NCT01036841·Phase 4·INTERVENTIONAL

Influence of Food-intake on Desmopressin Oral Tablets and MELT-formulation

Status

Completed

Phase

Phase 4

Enrollment

24

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

Alarm-treatment as well as Desmopressin, a synthetic analogue of human vasopressin, are considered the only evidence-based medicine (EBM) IA treatments in monosymptomatic nocturnal enuresis (MNE). Desmopressin exists in three different formulations for ambulant use: nasal spray, tablet and lyophilisate (MELT) each with differences in bioavailability (spray 2%, tablet 0.2%, MELT 0.5%). There 's insufficient evidence to confirm the actually used bioequivalent doses ( 10µg spray = 120µg MELT= 0.2mg tablet). Although so frequently used, very few pharmacokinetic and -dynamic data on desmopressin are available for children. Due to prolonged half life, associated with waterintoxication,the nasal spray has a black box warning from the FDA and is no longer recommended . For some authors oral formulations appear to be a safer alternative. However, based on clinical experience of less response rate with oral formulations, lower biodisponibility is suspected. Adult research confirms low bioavailability of tablets but also show major influences by food-intake and changes in gastro-intestinal motility. To achieve maximum efficacy, recommendations are to take desmopressin tablet 1 hour before bedtime and 2 hours after meal: this is unrealistic in schoolaged children since there never is 3 hours between evening meal and bedtime. In 2005 a dose response study demonstrated superior pharmaco-kinetic and dynamic properties for desmopressin Lyophilisate MELT formula. Since these results implicate superior action of MELT, often a change to MELT is recommended if there is a suboptimal response with tablet: sublingual absorption would eliminate the influence of food-intake. However, for this statement there's no evidence, since these tests were all conducted in children in fasting condition. Only one clinical study demonstrates bioequivalence for MELT and tablet. Hypothesis is that desmopressin MELT formulation has a better bioavailability when administered together with meal due to its sublingual absorption.

Interventions

Treatment arms and agents.

DRUG

desmopressin tablet

Administration of desmopressine tablet

DRUG

desmopressin MELT formulation

Administration of desmopressine MELT formulation

Timeline

From registration to results.

  1. First posted

    Dec 21, 2009

  2. Study start

    Dec 2009

  3. Primary completion

    Apr 2010

  4. Study completion

    Apr 2010

  5. Results posted

    Not reported

  6. Registry updated

    Feb 6, 2019

Outcomes

What the study measures.

Primary outcomes

Bioavailability of desmopressine MELT and tablet when taken with meal.

Time frame · at 1h, 2h and 6h post adminstration

Secondary outcomes

Pharmacokinetic and pharmacodynamic for desmopressine MELT and tablet.

Time frame · at 1h, 2h, 3h, 6h and 8h post administration

Eligibility

Who can take part.

Minimum age
6 Years
Maximum age
16 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * children aged 6-16 years old * with MNE and nocturnal polyuria * treated with desmopressin tablet, non or partial responders, for whom change to MELT formulation is indicated according to the international standard guidelines. Exclusion Criteria: * history of urologic disease, diurnal urinary incontinence, diabetes insipidus, urinary tract infection, clinically significant disease * No systemic use of antibiotics, diuretics, other medication that influences urinary concentrating mechanism * abnormalities of oral mucosa which could influence drugrelease or absorption

Study locations

1 registered sites.

Belgium. Showing up to 24 locations stored in the fast local snapshot.

University Hospital Ghent

Ghent, Belgium

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Desmopressin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.